ES2208942T3 - Proteinas e4 de adenovirus para inducir la muerte celular. - Google Patents

Proteinas e4 de adenovirus para inducir la muerte celular.

Info

Publication number
ES2208942T3
ES2208942T3 ES97935709T ES97935709T ES2208942T3 ES 2208942 T3 ES2208942 T3 ES 2208942T3 ES 97935709 T ES97935709 T ES 97935709T ES 97935709 T ES97935709 T ES 97935709T ES 2208942 T3 ES2208942 T3 ES 2208942T3
Authority
ES
Spain
Prior art keywords
e4orf4
polypeptide
sequence
cells
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97935709T
Other languages
English (en)
Spanish (es)
Inventor
Philip E. Branton
Gordon C. Shore
Jose G. Teodoro
Richard C. Marcellus
Josee N. Lavoie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2208942T3 publication Critical patent/ES2208942T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES97935709T 1996-07-05 1997-07-03 Proteinas e4 de adenovirus para inducir la muerte celular. Expired - Lifetime ES2208942T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2127396P 1996-07-05 1996-07-05
US21273P 1996-07-05
US2874096P 1996-10-22 1996-10-22
US28740P 1996-10-22

Publications (1)

Publication Number Publication Date
ES2208942T3 true ES2208942T3 (es) 2004-06-16

Family

ID=26694498

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97935709T Expired - Lifetime ES2208942T3 (es) 1996-07-05 1997-07-03 Proteinas e4 de adenovirus para inducir la muerte celular.

Country Status (10)

Country Link
EP (1) EP0951553B1 (de)
JP (1) JP2000515504A (de)
AT (1) ATE253117T1 (de)
AU (1) AU731924B2 (de)
CA (1) CA2259152C (de)
DE (1) DE69725882T2 (de)
DK (1) DK0951553T3 (de)
ES (1) ES2208942T3 (de)
PT (1) PT951553E (de)
WO (1) WO1998001563A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1157122A1 (de) * 1999-03-01 2001-11-28 Cell Genesys, Inc. Antineoplastische zusammensetzungen und deren verwendungen
WO2001004629A1 (en) * 1999-07-12 2001-01-18 Mcgill University E4orf4 and pp2a polypeptides, modulators, and mimetics for selectively inducing cell death
US7094529B2 (en) 2000-02-22 2006-08-22 Smithkline Beecham Corporation Bunyaviridal reaper proteins and uses therefore
DE60102802T2 (de) * 2000-02-22 2005-04-21 Glaxo Group Ltd Reaper proteine der bunyaviridae sowie verwendungen dieser
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
WO2002067857A2 (en) 2001-02-21 2002-09-06 Surromed, Inc. Modified annexin proteins and methods for preventing thrombosis
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
FR2827866B1 (fr) 2001-07-27 2004-12-10 Pasteur Institut Peptides synthetiques ou naturels liant la proteine phosphatase 2a, methode d'identification et utilisations
EP1327688A1 (de) * 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviren mit erhöhter Lysisfähigkeit
PT1497438E (pt) * 2002-04-25 2010-02-04 Crucell Holland Bv Meios e métodos para a produção de vectores de adenovírus
AU2003242585A1 (en) 2002-05-27 2003-12-12 Per Sonne Holm Novel use of adenoviruses and nucleic acids coding therefor
CA2408207A1 (fr) 2002-10-16 2004-04-16 Institut Pasteur Peptides liant la proteine phosphatase 2a et polynucleotides les codant
US20070110719A1 (en) 2003-11-14 2007-05-17 Holm Per S Novel use of adenoviruses and nucleic acids that code for said viruses
JP2021529184A (ja) * 2018-06-25 2021-10-28 オスペダーレ サン ラファエレ エス．アール．エル 遺伝子治療

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2726285B1 (fr) * 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
US5872005A (en) * 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
IL116816A (en) * 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US6281010B1 (en) * 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line

Also Published As

Publication number Publication date
DE69725882D1 (de) 2003-12-04
JP2000515504A (ja) 2000-11-21
CA2259152C (en) 2002-02-12
DE69725882T2 (de) 2004-07-29
AU3860197A (en) 1998-02-02
EP0951553A2 (de) 1999-10-27
CA2259152A1 (en) 1998-01-15
PT951553E (pt) 2004-02-27
WO1998001563A2 (en) 1998-01-15
DK0951553T3 (da) 2004-02-09
EP0951553B1 (de) 2003-10-29
AU731924B2 (en) 2001-04-05
ATE253117T1 (de) 2003-11-15
WO1998001563A3 (en) 1998-03-12

Similar Documents

Publication Publication Date Title
ES2208942T3 (es) Proteinas e4 de adenovirus para inducir la muerte celular.
US7033750B2 (en) Recombinant P53 adenovirus methods and compositions
Pim et al. Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth
ES2268704T3 (es) Nuevos peptidos y composiciones que modulan las apoptosis.
US7244617B2 (en) Diminishing viral gene expression by promoter replacement
US7772367B2 (en) C-terminal p53 palindromic peptide that induces apoptosis of cells with aberrant p53 and uses thereof
JP2011225571A (ja) Ｍｄｍ２タンパク質の腫瘍原活性のアンタゴニスト及び癌治療におけるその使用
JPH08507076A (ja) 新形成の治療及び予防のための細胞障害ウイルス
SK6598A3 (en) P16 expression constructs and their application in cancer therapy
WO2002019965A2 (en) Heat shock response and virus replication
ES2249773T3 (es) Nuevo implante y nuevo vector para el tratamiento de enfermedades adquiridas.
US6730662B1 (en) Adenovirus E4 proteins for inducing cell death
Norris et al. A fluorescent p53GFP fusion protein facilitates its detection in mammalian cells while retaining the properties of wild-type p53
US7163925B1 (en) p16 expression constructs and their application in cancer therapy
KR20070044868A (ko) 스트렙토라이신 ｏ 단백질을 암호화하는 유전자를 발현하는재조합 아데노바이러스 및 이를 유효성분으로 하는 항암용조성물
US6521602B1 (en) Anti-neoplastic compositions and uses thereof
Kulshreshtha Molecular characterization of 33K protein of bovine adenovirus type 3
US20030050266A1 (en) Anti-tumor effects of prostate carcinoma tumor antigen-1
KR20230112691A (ko) 바이러스 감염을 치료하기 위한 방법 및 조성물
JP2003501097A (ja) アデノウイルスｅ３／６．７ｋによるアポトーシスの阻害
JPH11507208A (ja) アポトーシス遺伝子１のヒトインヒビター